DK3709978T3 - Farmaceutisk oral formulering omfattende bakterier - Google Patents

Farmaceutisk oral formulering omfattende bakterier Download PDF

Info

Publication number
DK3709978T3
DK3709978T3 DK18803675.0T DK18803675T DK3709978T3 DK 3709978 T3 DK3709978 T3 DK 3709978T3 DK 18803675 T DK18803675 T DK 18803675T DK 3709978 T3 DK3709978 T3 DK 3709978T3
Authority
DK
Denmark
Prior art keywords
bacteria
oral formulation
pharmaceutical oral
pharmaceutical
formulation
Prior art date
Application number
DK18803675.0T
Other languages
English (en)
Inventor
Carole Schwintner
Marianne Robin
Hervé Affagard
Cédric Michenet
Amandine Bardy
Jean-François Dubuisson
Original Assignee
Biocodex
Maat Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocodex, Maat Pharma filed Critical Biocodex
Application granted granted Critical
Publication of DK3709978T3 publication Critical patent/DK3709978T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135Bacteria or derivatives thereof, e.g. probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891Coated capsules; Multilayered drug free capsule shells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DK18803675.0T 2017-11-17 2018-11-16 Farmaceutisk oral formulering omfattende bakterier DK3709978T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17306602.8A EP3485879A1 (en) 2017-11-17 2017-11-17 Pharmaceutical oral formulation comrpsing bacteria
PCT/EP2018/081650 WO2019097030A1 (en) 2017-11-17 2018-11-16 Pharmaceutical oral formulation comprising bacteria

Publications (1)

Publication Number Publication Date
DK3709978T3 true DK3709978T3 (da) 2023-06-12

Family

ID=60473460

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18803675.0T DK3709978T3 (da) 2017-11-17 2018-11-16 Farmaceutisk oral formulering omfattende bakterier

Country Status (19)

Country Link
US (1) US11141440B2 (da)
EP (2) EP3485879A1 (da)
JP (1) JP7253546B2 (da)
KR (1) KR20200088395A (da)
CN (1) CN111343972B (da)
AU (1) AU2018367230B2 (da)
CA (1) CA3079627C (da)
DK (1) DK3709978T3 (da)
ES (1) ES2947578T3 (da)
FI (1) FI3709978T3 (da)
HR (1) HRP20230647T1 (da)
HU (1) HUE062579T2 (da)
IL (1) IL273740B2 (da)
LT (1) LT3709978T (da)
PL (1) PL3709978T3 (da)
PT (1) PT3709978T (da)
RS (1) RS64290B1 (da)
SI (1) SI3709978T1 (da)
WO (1) WO2019097030A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111413503A (zh) * 2020-03-28 2020-07-14 浙江大学 骨桥蛋白作为靶分子在调节高脂饮食引起的肥胖中的应用
EP3895716A1 (en) 2020-04-17 2021-10-20 Maat Pharma Fmt performance prediction test to guide and optimize therapeutic management of gvhd patients
CN111690044B (zh) * 2020-05-06 2022-03-01 中南大学湘雅二医院 Amuc1100蛋白的用途
IL303884A (en) 2020-12-23 2023-08-01 Maat Pharma France Sa A Conseil Dadministration A method for expanding a complex community of microorganisms
CN112826836A (zh) * 2021-01-08 2021-05-25 深圳未知君生物科技有限公司 一种粪菌口服制剂及其制备方法
AU2022308614A1 (en) * 2021-07-09 2024-02-22 Evonik Operations Gmbh Hard shell capsules having improved colon release
CN117603884B (zh) * 2024-01-17 2024-03-26 广州同康生物科技有限公司 一种嗜黏蛋白阿克曼氏菌菌粉及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG80553A1 (en) * 1995-07-20 2001-05-22 Tanabe Seiyaku Co Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract
CN101801356B (zh) * 2007-09-21 2016-10-19 赢创罗姆有限公司 耐受乙醇影响的非阿片类的pH依赖性受控释放的药物组合物
AU2013350328A1 (en) * 2012-11-26 2015-07-09 Thomas Julius Borody Compositions for the restoration of a fecal microbiota and methods for making and using them
BR112015023124A2 (pt) * 2013-03-14 2017-07-18 Therabiome Llc liberação de organismos probióticos e/ou agentes terapêuticos almejada para o trato gastrintestinal
US9775814B2 (en) * 2014-06-20 2017-10-03 Patheon Softgels Inc. Enteric soft capsule compositions
IL251844B2 (en) 2014-10-23 2024-04-01 Roussy Inst Gustave Methods and products for modulation of microbiota composition to improve the effectiveness of cancer treatment with immune checkpoint blockade
CN104490848B (zh) * 2014-12-31 2018-01-30 四川峨嵋山药业有限公司 一种雷替曲塞结肠定位微丸及其制备方法
FR3035328B1 (fr) 2015-04-24 2019-08-23 Maat Pharma Procede de preparation d'un echantillon de microbiote fecal
IL281424B2 (en) 2015-06-09 2023-10-01 Rebiotix Inc Microbiota restoration treatment preparations and production methods
FR3045383B1 (fr) 2015-12-18 2019-06-14 Maat Pharma Procede de lyophilisation d'un echantillon de microbiote fecal

Also Published As

Publication number Publication date
US11141440B2 (en) 2021-10-12
RS64290B1 (sr) 2023-07-31
LT3709978T (lt) 2023-08-10
CN111343972A (zh) 2020-06-26
FI3709978T3 (fi) 2023-06-28
EP3709978B1 (en) 2023-04-05
HUE062579T2 (hu) 2023-11-28
SI3709978T1 (sl) 2023-09-29
CN111343972B (zh) 2022-10-28
AU2018367230A1 (en) 2020-05-07
JP2021503452A (ja) 2021-02-12
PT3709978T (pt) 2023-07-11
IL273740B2 (en) 2024-04-01
CA3079627C (en) 2023-06-13
ES2947578T3 (es) 2023-08-11
KR20200088395A (ko) 2020-07-22
CA3079627A1 (en) 2019-05-23
AU2018367230B2 (en) 2023-06-08
EP3485879A1 (en) 2019-05-22
HRP20230647T1 (hr) 2023-09-29
WO2019097030A1 (en) 2019-05-23
JP7253546B2 (ja) 2023-04-06
IL273740A (en) 2020-05-31
PL3709978T3 (pl) 2023-10-02
EP3709978A1 (en) 2020-09-23
EP3709978B8 (en) 2023-05-31
US20200345790A1 (en) 2020-11-05
IL273740B1 (en) 2023-12-01

Similar Documents

Publication Publication Date Title
GB201807942D0 (en) Pharmaceutical formulation
DK3709978T3 (da) Farmaceutisk oral formulering omfattende bakterier
MA50541A (fr) Formulations pharmaceutiques
MA42303A (fr) Formulations pharmaceutiques
MA46867A (fr) Formulations pharmaceutiques
DK3634377T3 (da) Farmaceutisk formulering
BR112017013012A2 (pt) compostos de indenil, composições farmacêuticas e usos médicos destes
MA44987A (fr) Formulations de médicaments améliorées
MA49837A (fr) Compositions pharmaceutiques
ZA202102871B (en) Pharmaceutical formulation
IL278927A (en) pharmaceutical preparation
DK3436120T3 (da) Oral medicinsk indretning
DK3280447T3 (da) Farmaceutiske formuleringer
DK3601277T3 (da) Farmaceutisk formulering
DK3313370T3 (da) Oftalmologisk farmaceutisk sammensætning
MA51009A (fr) Composition de soins buccaux
IL275144A (en) Pharmacy preparation
MA49625A (fr) Compositions pharmaceutiques
ZA201804275B (en) Oral pharmaceutical composition comprising taste-masked n-acetylcysteine
DK3481370T3 (da) Farmaceutisk sammensætning omfattende benzydamin
GB201719873D0 (en) Pharmaceutical formulation
PT3373945T (pt) Uma formulação de fármaco oral que inclui silibina
BR112017004882A2 (pt) composição farmacêutica oral.
TH1501007612A (th) อมอร์ฟัสลีเทอร์โมเวียร์และสูตรผสมของแข็งทางเภสัชกรรมของมันสำหรับให้เข้าทางปาก